United States - English - NLM (National Library of Medicine)

aspen global inc. - busulfan (unii: g1ln9045dk) (busulfan - unii:g1ln9045dk) - busulfan 2 mg - myleran (busulfan) is indicated for the palliative treatment of chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia. myleran is contraindicated in patients in whom a definitive diagnosis of chronic myelogenous leukemia has not been firmly established. myleran is contraindicated in patients who have previously suffered a hypersensitivity reaction to busulfan or any other component of the preparation.

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

glaxowellcome - busulfan - tablet - 2 mg

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

aspen pharma trading limited (aptl), ireland - busulfan - tablet - 2 mg

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

aspen - busulfan - tablet - 2 mg

United States - English - NLM (National Library of Medicine)

woodward pharma services llc - busulfan (unii: g1ln9045dk) (busulfan - unii:g1ln9045dk) - myleran (busulfan) is indicated for the palliative treatment of chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia. myleran is contraindicated in patients in whom a definitive diagnosis of chronic myelogenous leukemia has not been firmly established. myleran is contraindicated in patients who have previously suffered a hypersensitivity reaction to busulfan or any other component of the preparation.

United States - English - NLM (National Library of Medicine)

waylis therapeutics llc - busulfan (unii: g1ln9045dk) (busulfan - unii:g1ln9045dk) - myleran (busulfan) is indicated for the palliative treatment of chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia. myleran is contraindicated in patients in whom a definitive diagnosis of chronic myelogenous leukemia has not been firmly established. myleran is contraindicated in patients who have previously suffered a hypersensitivity reaction to busulfan or any other component of the preparation.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

aspen medical products malaysia sdn bhd - busulphan -

Egypt - English - EDA (Egyptian Drug Authority)

glaxo smithkline-egypt - coated tablet - 2 mg

Canada - English - Health Canada

aspen pharmacare canada inc. - chlorambucil - tablet - 2mg - chlorambucil 2mg - antineoplastic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - tioguanine, quantity: 40 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; stearic acid; magnesium stearate; potato starch; acacia - indications as at 10 october 2005: acute myeloblastic leukaemia. less commonly, chronic granulocytic (myelocytic, myeloid, myelogenous) leukaemia. although superior results are generally obtained with busulphan (myleran) in the treatment of chronic granulocytic leukaemia. lanvis may be useful during blast crises or periods of thrombocytopenia induced by busulphan or other therapy. a degree of cross resistance exists between lanvis (thioguanine) and puri-nethol (mercaptopurine) and generally it is not to be expected that patients who no longer respond to mercaptopurine will respond to thioguanine or vice versa. unlike mercaptopurine the detoxification of lanvis is not dependent on xanthine oxidase, hence therapy with lanvis is not affected by the xanthine oxidase inhibitor, allopurinol (zyloprim). recent evidence suggests that lanvis is particularly useful in concurrent or sequelist combination with other antineoplastic drugs, e.g., cytosine arabinoside. not effective for the treatment of chronic lymphocytic l